Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into real‐world trials
Purpose To assess the feasibility of using Clinical Practice Research Datalink (CPRD) data for identifying populations of patients with chronic obstructive pulmonary disease (COPD) eligible for a hypothetical pragmatic trial. Methods A retrospective multidatabase cohort study using CPRD primary care...
Gespeichert in:
Veröffentlicht in: | Pharmacoepidemiology and drug safety 2021-04, Vol.30 (4), p.472-481 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 481 |
---|---|
container_issue | 4 |
container_start_page | 472 |
container_title | Pharmacoepidemiology and drug safety |
container_volume | 30 |
creator | Requena, Gema Wolf, Achim Williams, Rachael Dedman, Daniel Quint, Jennifer K. Murray‐Thomas, Tarita Pimenta, Jeanne M. |
description | Purpose
To assess the feasibility of using Clinical Practice Research Datalink (CPRD) data for identifying populations of patients with chronic obstructive pulmonary disease (COPD) eligible for a hypothetical pragmatic trial.
Methods
A retrospective multidatabase cohort study using CPRD primary care and linked secondary care data to describe the characteristics of populations of patients with COPD. Patients' demographic and lifestyle factors, comorbidity profile, spirometry measurements and treatment changes were evaluated, as was the distribution of follow‐up time and types of losses during follow‐up. Characteristics were evaluated using descriptive statistics.
Results
A total of 322 991 patients from 1148 primary care practices in the United Kingdom across two CPRD primary care databases, CPRD GOLD and CPRD Aurum, were potentially eligible to participate in a hypothetical trial using CPRD, starting on 31 December 2017. Patients with COPD in CPRD GOLD and CPRD Aurum were comparable in terms of age (median age 70 vs. 68 years), gender (50% vs. 52% male), disease severity (e.g., 25% vs. 24% Medical Research Council [MRC] dyspnoea score grades 3–5) and history of respiratory conditions (e.g., 43% vs. 38% asthma). High proportions of patients with COPD in CPRD GOLD and CPRD Aurum were available on 31 December 2012 for follow‐up at 1, 2, and 5 years (92%, 85% and 67%, respectively).
Conclusions
Patients and data from CPRD GOLD and CPRD Aurum were comparable across key aspects relevant to COPD trials. A pragmatic trial using CPRD to recruit patients with COPD is scientifically feasible. |
doi_str_mv | 10.1002/pds.5188 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7986187</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2494657226</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4388-f171fff77d519512aade6da4ed3f4f5e0e21c29240aa6e5f32e04454e042c5513</originalsourceid><addsrcrecordid>eNp1kdtqFTEUhgdR7EHBJ5CAN72ZmuNM5kaQXatCweLhOmQnK92p2ZMxyXSz73yEvoHv5pOYbWs9gDdZP6w_H__ib5onBB8TjOnzyeZjQaS81-wTPAwtEaK_v9OCtVJ0w15zkPMlxnU38IfNHmOsk5Li_ebbKejslz74skXRoTn78QItgh-90QGdJ22KN4DeQwadzAqd6KLr9jOyVaASkbcwFu-2aNLFV5nRxpcVMqsUKwPFZS5prpArQNMc1nHUaYusr7gMu_8wphiQH6tMoMP3r9ebmIJFJXkd8qPmgasDHt_Ow-bT6auPizft2bvXbxcvz1rDmZStIz1xzvW9FWQQhGptobOag2WOOwEYKDF0oBxr3YFwjALmXPD6UiMEYYfNixvuNC_XYE09JOmgpuTXNa-K2qu_N6NfqYt4pfpBdkT2FXB0C0jxywy5qLXPBkLQI8Q5K8p7xrFkXVetz_6xXsY5jfW86hp4J3pKu99Ak2LOCdxdGILVrnVVW1e71qv16Z_h74y_aq6G9saw8QG2_wWp85MPP4E_AEFQu-I</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2494657226</pqid></control><display><type>article</type><title>Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into real‐world trials</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Requena, Gema ; Wolf, Achim ; Williams, Rachael ; Dedman, Daniel ; Quint, Jennifer K. ; Murray‐Thomas, Tarita ; Pimenta, Jeanne M.</creator><creatorcontrib>Requena, Gema ; Wolf, Achim ; Williams, Rachael ; Dedman, Daniel ; Quint, Jennifer K. ; Murray‐Thomas, Tarita ; Pimenta, Jeanne M.</creatorcontrib><description>Purpose
To assess the feasibility of using Clinical Practice Research Datalink (CPRD) data for identifying populations of patients with chronic obstructive pulmonary disease (COPD) eligible for a hypothetical pragmatic trial.
Methods
A retrospective multidatabase cohort study using CPRD primary care and linked secondary care data to describe the characteristics of populations of patients with COPD. Patients' demographic and lifestyle factors, comorbidity profile, spirometry measurements and treatment changes were evaluated, as was the distribution of follow‐up time and types of losses during follow‐up. Characteristics were evaluated using descriptive statistics.
Results
A total of 322 991 patients from 1148 primary care practices in the United Kingdom across two CPRD primary care databases, CPRD GOLD and CPRD Aurum, were potentially eligible to participate in a hypothetical trial using CPRD, starting on 31 December 2017. Patients with COPD in CPRD GOLD and CPRD Aurum were comparable in terms of age (median age 70 vs. 68 years), gender (50% vs. 52% male), disease severity (e.g., 25% vs. 24% Medical Research Council [MRC] dyspnoea score grades 3–5) and history of respiratory conditions (e.g., 43% vs. 38% asthma). High proportions of patients with COPD in CPRD GOLD and CPRD Aurum were available on 31 December 2012 for follow‐up at 1, 2, and 5 years (92%, 85% and 67%, respectively).
Conclusions
Patients and data from CPRD GOLD and CPRD Aurum were comparable across key aspects relevant to COPD trials. A pragmatic trial using CPRD to recruit patients with COPD is scientifically feasible.</description><identifier>ISSN: 1053-8569</identifier><identifier>EISSN: 1099-1557</identifier><identifier>DOI: 10.1002/pds.5188</identifier><identifier>PMID: 33368820</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Inc</publisher><subject>Asthma ; Chronic obstructive pulmonary disease ; Clinical medicine ; Clinical trials ; Dyspnea ; electronic health record ; feasibility studies ; general practice ; Lung diseases ; Medical research ; Obstructive lung disease ; Original ; Patients ; Practice research ; Primary care ; primary health care ; real world clinical trials ; Respiration</subject><ispartof>Pharmacoepidemiology and drug safety, 2021-04, Vol.30 (4), p.472-481</ispartof><rights>2020 GSK. published by John Wiley & Sons Ltd.</rights><rights>2020 GSK. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd.</rights><rights>2020. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 GSK. published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4388-f171fff77d519512aade6da4ed3f4f5e0e21c29240aa6e5f32e04454e042c5513</citedby><cites>FETCH-LOGICAL-c4388-f171fff77d519512aade6da4ed3f4f5e0e21c29240aa6e5f32e04454e042c5513</cites><orcidid>0000-0002-1889-6656 ; 0000-0001-9007-6292</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpds.5188$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpds.5188$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33368820$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Requena, Gema</creatorcontrib><creatorcontrib>Wolf, Achim</creatorcontrib><creatorcontrib>Williams, Rachael</creatorcontrib><creatorcontrib>Dedman, Daniel</creatorcontrib><creatorcontrib>Quint, Jennifer K.</creatorcontrib><creatorcontrib>Murray‐Thomas, Tarita</creatorcontrib><creatorcontrib>Pimenta, Jeanne M.</creatorcontrib><title>Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into real‐world trials</title><title>Pharmacoepidemiology and drug safety</title><addtitle>Pharmacoepidemiol Drug Saf</addtitle><description>Purpose
To assess the feasibility of using Clinical Practice Research Datalink (CPRD) data for identifying populations of patients with chronic obstructive pulmonary disease (COPD) eligible for a hypothetical pragmatic trial.
Methods
A retrospective multidatabase cohort study using CPRD primary care and linked secondary care data to describe the characteristics of populations of patients with COPD. Patients' demographic and lifestyle factors, comorbidity profile, spirometry measurements and treatment changes were evaluated, as was the distribution of follow‐up time and types of losses during follow‐up. Characteristics were evaluated using descriptive statistics.
Results
A total of 322 991 patients from 1148 primary care practices in the United Kingdom across two CPRD primary care databases, CPRD GOLD and CPRD Aurum, were potentially eligible to participate in a hypothetical trial using CPRD, starting on 31 December 2017. Patients with COPD in CPRD GOLD and CPRD Aurum were comparable in terms of age (median age 70 vs. 68 years), gender (50% vs. 52% male), disease severity (e.g., 25% vs. 24% Medical Research Council [MRC] dyspnoea score grades 3–5) and history of respiratory conditions (e.g., 43% vs. 38% asthma). High proportions of patients with COPD in CPRD GOLD and CPRD Aurum were available on 31 December 2012 for follow‐up at 1, 2, and 5 years (92%, 85% and 67%, respectively).
Conclusions
Patients and data from CPRD GOLD and CPRD Aurum were comparable across key aspects relevant to COPD trials. A pragmatic trial using CPRD to recruit patients with COPD is scientifically feasible.</description><subject>Asthma</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Dyspnea</subject><subject>electronic health record</subject><subject>feasibility studies</subject><subject>general practice</subject><subject>Lung diseases</subject><subject>Medical research</subject><subject>Obstructive lung disease</subject><subject>Original</subject><subject>Patients</subject><subject>Practice research</subject><subject>Primary care</subject><subject>primary health care</subject><subject>real world clinical trials</subject><subject>Respiration</subject><issn>1053-8569</issn><issn>1099-1557</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><recordid>eNp1kdtqFTEUhgdR7EHBJ5CAN72ZmuNM5kaQXatCweLhOmQnK92p2ZMxyXSz73yEvoHv5pOYbWs9gDdZP6w_H__ib5onBB8TjOnzyeZjQaS81-wTPAwtEaK_v9OCtVJ0w15zkPMlxnU38IfNHmOsk5Li_ebbKejslz74skXRoTn78QItgh-90QGdJ22KN4DeQwadzAqd6KLr9jOyVaASkbcwFu-2aNLFV5nRxpcVMqsUKwPFZS5prpArQNMc1nHUaYusr7gMu_8wphiQH6tMoMP3r9ebmIJFJXkd8qPmgasDHt_Ow-bT6auPizft2bvXbxcvz1rDmZStIz1xzvW9FWQQhGptobOag2WOOwEYKDF0oBxr3YFwjALmXPD6UiMEYYfNixvuNC_XYE09JOmgpuTXNa-K2qu_N6NfqYt4pfpBdkT2FXB0C0jxywy5qLXPBkLQI8Q5K8p7xrFkXVetz_6xXsY5jfW86hp4J3pKu99Ak2LOCdxdGILVrnVVW1e71qv16Z_h74y_aq6G9saw8QG2_wWp85MPP4E_AEFQu-I</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Requena, Gema</creator><creator>Wolf, Achim</creator><creator>Williams, Rachael</creator><creator>Dedman, Daniel</creator><creator>Quint, Jennifer K.</creator><creator>Murray‐Thomas, Tarita</creator><creator>Pimenta, Jeanne M.</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1889-6656</orcidid><orcidid>https://orcid.org/0000-0001-9007-6292</orcidid></search><sort><creationdate>202104</creationdate><title>Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into real‐world trials</title><author>Requena, Gema ; Wolf, Achim ; Williams, Rachael ; Dedman, Daniel ; Quint, Jennifer K. ; Murray‐Thomas, Tarita ; Pimenta, Jeanne M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4388-f171fff77d519512aade6da4ed3f4f5e0e21c29240aa6e5f32e04454e042c5513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Asthma</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Dyspnea</topic><topic>electronic health record</topic><topic>feasibility studies</topic><topic>general practice</topic><topic>Lung diseases</topic><topic>Medical research</topic><topic>Obstructive lung disease</topic><topic>Original</topic><topic>Patients</topic><topic>Practice research</topic><topic>Primary care</topic><topic>primary health care</topic><topic>real world clinical trials</topic><topic>Respiration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Requena, Gema</creatorcontrib><creatorcontrib>Wolf, Achim</creatorcontrib><creatorcontrib>Williams, Rachael</creatorcontrib><creatorcontrib>Dedman, Daniel</creatorcontrib><creatorcontrib>Quint, Jennifer K.</creatorcontrib><creatorcontrib>Murray‐Thomas, Tarita</creatorcontrib><creatorcontrib>Pimenta, Jeanne M.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pharmacoepidemiology and drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Requena, Gema</au><au>Wolf, Achim</au><au>Williams, Rachael</au><au>Dedman, Daniel</au><au>Quint, Jennifer K.</au><au>Murray‐Thomas, Tarita</au><au>Pimenta, Jeanne M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into real‐world trials</atitle><jtitle>Pharmacoepidemiology and drug safety</jtitle><addtitle>Pharmacoepidemiol Drug Saf</addtitle><date>2021-04</date><risdate>2021</risdate><volume>30</volume><issue>4</issue><spage>472</spage><epage>481</epage><pages>472-481</pages><issn>1053-8569</issn><eissn>1099-1557</eissn><abstract>Purpose
To assess the feasibility of using Clinical Practice Research Datalink (CPRD) data for identifying populations of patients with chronic obstructive pulmonary disease (COPD) eligible for a hypothetical pragmatic trial.
Methods
A retrospective multidatabase cohort study using CPRD primary care and linked secondary care data to describe the characteristics of populations of patients with COPD. Patients' demographic and lifestyle factors, comorbidity profile, spirometry measurements and treatment changes were evaluated, as was the distribution of follow‐up time and types of losses during follow‐up. Characteristics were evaluated using descriptive statistics.
Results
A total of 322 991 patients from 1148 primary care practices in the United Kingdom across two CPRD primary care databases, CPRD GOLD and CPRD Aurum, were potentially eligible to participate in a hypothetical trial using CPRD, starting on 31 December 2017. Patients with COPD in CPRD GOLD and CPRD Aurum were comparable in terms of age (median age 70 vs. 68 years), gender (50% vs. 52% male), disease severity (e.g., 25% vs. 24% Medical Research Council [MRC] dyspnoea score grades 3–5) and history of respiratory conditions (e.g., 43% vs. 38% asthma). High proportions of patients with COPD in CPRD GOLD and CPRD Aurum were available on 31 December 2012 for follow‐up at 1, 2, and 5 years (92%, 85% and 67%, respectively).
Conclusions
Patients and data from CPRD GOLD and CPRD Aurum were comparable across key aspects relevant to COPD trials. A pragmatic trial using CPRD to recruit patients with COPD is scientifically feasible.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Inc</pub><pmid>33368820</pmid><doi>10.1002/pds.5188</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-1889-6656</orcidid><orcidid>https://orcid.org/0000-0001-9007-6292</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1053-8569 |
ispartof | Pharmacoepidemiology and drug safety, 2021-04, Vol.30 (4), p.472-481 |
issn | 1053-8569 1099-1557 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7986187 |
source | Wiley Online Library Journals Frontfile Complete |
subjects | Asthma Chronic obstructive pulmonary disease Clinical medicine Clinical trials Dyspnea electronic health record feasibility studies general practice Lung diseases Medical research Obstructive lung disease Original Patients Practice research Primary care primary health care real world clinical trials Respiration |
title | Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into real‐world trials |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T23%3A08%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Feasibility%20of%20using%20Clinical%20Practice%20Research%20Datalink%20data%20to%20identify%20patients%20with%20chronic%20obstructive%20pulmonary%20disease%20to%20enrol%20into%20real%E2%80%90world%20trials&rft.jtitle=Pharmacoepidemiology%20and%20drug%20safety&rft.au=Requena,%20Gema&rft.date=2021-04&rft.volume=30&rft.issue=4&rft.spage=472&rft.epage=481&rft.pages=472-481&rft.issn=1053-8569&rft.eissn=1099-1557&rft_id=info:doi/10.1002/pds.5188&rft_dat=%3Cproquest_pubme%3E2494657226%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2494657226&rft_id=info:pmid/33368820&rfr_iscdi=true |